All In Biotech

Free tool

FAERS Monitor: Baxfendy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219878 or its brand name (Baxfendy, Baxdrostat). Reports on generic versions are filed under their own applications.

Reports

273

Serious

83

30% of reports

Hospitalization

33

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hyponatraemia26
  • dizziness22
  • muscle spasms21
  • hyperkalaemia19
  • blood potassium increased17
  • blood sodium decreased14
  • glomerular filtration rate decreased14
  • headache14
  • blood pressure increased12
  • nausea12
  • blood pressure decreased11
  • hypotension10
  • hypertension9
  • blood creatinine increased7
  • fatigue7

Reports by year received

View as table
YearReports
2026273

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,886 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
glomerular filtration rate decreasedSignal1487.952.71,117
blood potassium increasedSignal1780.851.01,261
blood sodium decreasedSignal1457.334.4719
hyperkalaemiaSignal1941.827.1717
hyponatraemiaSignal2635.624.7842
blood pressure decreasedSignal1112.87.1108
muscle spasmsSignal218.85.8139
blood creatinine increasedSignal78.34.038
blood pressure increasedSignal126.03.546
hypotensionSignal103.82.118
dizzinessSignal223.42.336
hypertensionSignal93.31.712
headache141.71.04
nausea121.20.70
fatigue70.70.31

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.